<DOC>
	<DOC>NCT02288208</DOC>
	<brief_summary>This study evaluates the addition of birinapant in subjects with chronic Hepatitis B who are currently receiving anti-viral therapy with either tenofovir or entecavir. Patients will receive either birinapant or placebo in addition to their anti-viral therapy.</brief_summary>
	<brief_title>Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Documented history of chronic Hepatitis B infection currently being treated with tenofovir or entecavir for at least 3 months Measurable titer of HBsAg HBV DNA level &lt; 2 log copies/mL or 10² copies/mL No more than ChildPugh score of 5 plus a valid FibroScan® of at least 10 readings with a median score of &lt;7 and interquartile range of &lt; 30% Adequate liver function, aspartate AST and ALT ≤2 x ULN Adequate renal function as evidenced by creatinine ≤2 mg/dL Participation in any interventional study within 4 weeks prior to Screening Known HIV infection, Hepatitis C, or other significant hepatic disorder including cirrhosis (ChildPugh Class B or C) Serious illness or autoimmune disease or other known liver disease Uncontrolled hypertension Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications, or clinically significant cardiac disease Currently breast feeding, pregnant or planning on becoming pregnant Known allergy or hypersensitivity to any of the formulation components of birinapant or placebo, including citric acid History of cranial nerve palsy Current treatment with antiTNF therapies or has received treatment with antiTNF therapies within the last 6 months Use of nonsteroidal antiinflammatory drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>